Search

Fendiline

It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.

Idecabtagene vicleucel

[A232608] Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and [brexucabtagene autoleucel]. … [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

Lucanthone

It is currently being tested as a radiation sensitizer. … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

Kaolin

Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. … Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics.

Yellow fever vaccine

The World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border … Symptoms of Yellow fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure [L1655].

Butenafine

Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epo...

Citrus bioflavonoids

Rivanicline

It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. … It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8.

Roflumilast

[L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis. … [A251385] The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4 is thought to mediate its disease-modifying effects, although its precise mechanism of action has yet

Idarucizumab

As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease … , concomitant NSAID or warfarin use, etc).